Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218704

SCHEMBL23218704

SCHEMBL23218704

CCOC(=O)Cc1ccc(OC)cc1OCc1nn(C)c2ccc(-c3ccnc(CN)c3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 1/20 0.39
▸ DPP4 P27487 2/20 0.39
▸ CSF1R P07333 3/20 0.36
▸ PDGFRB P09619 3/20 0.36
▸ KDM4E B2RXH2 4/20 0.34
▸ MAPT P10636 4/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ HPGD P15428 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MET P08581 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592684 0.90 CFD (0.37) CFDCSF1RPDGFRBMETPDGFRA
SCHEMBL23218690 0.90 CFD (0.37) CFDCSF1RPDGFRBMETPDGFRA
SCHEMBL29852718 0.88 CFD (0.52) CFDDPP4KDM4EMAPTALDH1A1
SCHEMBL23218829 0.88 CFD (0.52) CFDDPP4KDM4EMAPTALDH1A1
SCHEMBL29852921 0.87 DPP4 (0.39) CFDDPP4CSF1RPDGFRBKDM4E
SCHEMBL23218950 0.87 DPP4 (0.39) CFDDPP4CSF1RPDGFRBKDM4E
SCHEMBL29122485 0.87 ALDH1A1 (0.39) CFDDPP4CSF1RPDGFRBKDM4E
SCHEMBL23219030 0.84 CFD (0.42) CFDDPP4KDM4EMAPTALDH1A1
SCHEMBL29853133 0.84 CFD (0.42) CFDDPP4KDM4EMAPTALDH1A1
SCHEMBL29122309 0.83 CFD (0.37) CFDDPP4CSF1RPDGFRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885DPP4 1386/4885CSF1R 340/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885DPP4 1004/4885CSF1R 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.